Navigation Links
Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced it has re-scheduled its presentation time at the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, FL to Thursday, May 1, 2008 at 3:00 p.m. ET / 12:00 p.m. PT. Previously, the presentation had been scheduled for 9:20 a.m. ET / 6:20 a.m. PT. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
2. Amylin Pharmaceuticals to Webcast First Quarter Results
3. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
4. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
5. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
6. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
10. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
11. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... 14, 2014 The largest international professional organization ... and therapeutic derivatives thereof has endorsed an educational ... about the challenges of adulterated herb and botanical ... The Society for Medicinal Plant and ...
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... launch product immediately, NATICK, Mass., April 17 ... announced that it has received approval for,the sale ... Canada. The Company reported that Health Canada,s Therapeutic,Products ... medical devices, has approved its use. The Company ...
... Syngenta today,announced that it will build a new biotech ... be on early-stage evaluation of GM and,native traits for ... areas of yield,improvement, drought resistance, disease control and biomass ... scope and will complement,Syngenta,s biotech research activities in the ...
... NexGenix Pharmaceuticals, presented,data on its Hsp90 inhibitor ... AACR,in San Diego today. The company presented data ... several novel, radicicol-based,Hsp90 inhibitors in its compound series., ... xenograft models,without evidence for liver and kidney toxicity. ...
Cached Biology Technology:Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 2Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System 3Syngenta To Build Major Global Biotech Research Center in Beijing, China 2Syngenta To Build Major Global Biotech Research Center in Beijing, China 3NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3
(Date:4/18/2014)... to the story of how barnyard chickens came to be, ... journal Proceedings of the National Academy of Sciences . ... 200-2300 years ago in Europe, researchers report that just a ... different from the chickens we know today. , The results ... domestic chickens -- such as their yellowish skin -- only ...
(Date:4/17/2014)... under clinical trials to treat tuberculosis could be the ... against various bacteria, fungal infections and parasites, yet evade ... chemists and collaborators. , Led by U. of I. ... ways the drug SQ109 attacks the tuberculosis bacterium, how ... from yeast to malaria and how targeting multiple ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
Breaking Biology News(10 mins):Ancient DNA offers clues to how barnyard chickens came to be 2Multitarget TB drug could treat other diseases, evade resistance 2Fish consumption advisories fail to cover all types of contaminants 2
... patients, own immune cells to target tumors have yielded promising ... also receive large doses of drugs designed to help immune ... Now a team of MIT engineers has devised a ... the backs of the cells sent in to fight the ...
... expensive DNA sequencing strategy, scientists have discovered genetic alterations ... rare disorder that causes multiple birth defects and mental ... new approach sequences just the exome, the 1-2 percent ... Kabuki syndrome, which has an estimated incidence of ...
... Stanley, Inc. (NYSE: www.stanleyassociates.com for ... this press release about our expectations about future ... the words "estimates," "anticipates," "plans," "expects" and similar ... the Private Securities Litigation Reform Act of 1995. ...
Cached Biology News:Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 2Drugs encased in nanoparticles travel to tumors on the surface of immune-system cells 3Discovered gene causes Kabuki syndrome 2Discovered gene causes Kabuki syndrome 3
... FLISP Assay with FAM-Labeled Substrate (green ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
Request Info...
... Array (MSTA) slides were designed to study protein ... multiple species. Tissue slices from three different ... can then be treated as a single histological ... situ hybridization. This format allows a ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
Biology Products: